Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about UTHR, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Dinutuximab FDA approved Mar 2015 · Unituxin |
Neuroblastoma | Phase 2 · NCT06450041 | Recruiting |
| Treprostinil | Pulmonary Arterial Hypertension | Phase 4 · NCT05203510 | Active not recruiting |
| Ralinepag | PAH | Phase 3 · NCT03683186 | Enrolling by invitation |
| Inhaled treprostinil | Pulmonary Hypertension | Phase 3 · NCT03794583 | Terminated |
| Universal Donor (UD) TGFβi NK Cells | Neuroblastoma | Phase 2 · NCT06450041 | Recruiting |
| Irinotecan | Neuroblastoma | Phase 2 · NCT06450041 | Recruiting |
| GGTA1 KO Thymokidney | ESRD (End-Stage Renal Disease) | Phase 1/2 · NCT07224763 | Recruiting |
| Cytotoxic Chemotherapeutic Agent | Neuroblastoma | Phase 2 · NCT05421897 | Active not recruiting |
| 10 GE Xenokidney | ESRD (End-Stage Renal Disease) | Phase 1/2 · NCT06878560 | Recruiting |
| Natural Killer Cell | Neuroblastoma | Phase 1 · NCT02573896 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not UTHR's own candidates): Vorinostat, Temozolomide, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Lenalidomide, Potassium Iodide, Sargramostim.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
UTHR holds $3.5B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when UTHR files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Vanguard Capital Management | Institution (13G, 5%+) | 2,278,348 | 5.35% | 2026-03-31 |
| Martine A Rothblatt Chairperson & CEO, Director · +24,410 options |
Insider | 49,581 | 0.12% | 2026-11-13 |
| Paul A Mahon EVP & GENERAL COUNSEL · +22,640 options |
Insider | 45,172 | 0.11% | 2026-11-05 |
| Nilda Mesa Director · +6,430 options |
Insider | 5,580 | 0.01% | 2026-09-14 |
| Christopher Patusky Director · +3,000 options |
Insider | 3,240 | 0.01% | 2026-11-09 |
Share count 42,588,726 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for UTHR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →